SIETES :: 93128 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations. N Engl J Med 2020:16 de octubre. [Ref.ID 103747]

2.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020:13 de octubre. [Ref.ID 103744]

3.

Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 2020;371:7 de octubre. [Ref.ID 103742]

4.

Parsons L. Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail. PMLiVE 2020:12 de octubre. [Ref.ID 103741]

5.

Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020:30 de septiembre. [Ref.ID 103735]

6.

Parsons L. J&J halts COVID-19 vaccine study after unexplained participant illness . PMLiVE 2020:13 de octubre. [Ref.ID 103734]

7.

Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Bateman BT. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine 2020;17:1 de septiembre. [Ref.ID 103726]

8.

Anónimo. CDER proposes withdrawal of approval for Makena . U.S. Food and Drug Administration 2020:10 de mayo. [Ref.ID 103725]

9.

Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]

10.

Samper E. Las farmacéuticas ganan: los estados europeos indemnizarán por efectos inesperados de las vacunas contra el coronavirus. eldiario.es 2020:15 de septiembre. [Ref.ID 103721]

11.

Sharrets J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med 2020;383:10 de septiembe. [Ref.ID 103713]

12.

Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, Huybrechts KF. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry 2020:1. [Ref.ID 103710]

13.

Zhang S. America is running low on a crucial resource for COVID-19 vaccines The country is facing a monkey shortage.. Nature Briefing 2020:31 de agosto. [Ref.ID 103708]

14.

Pichel J. Ni la rusa ni las chinas: estas son las vacunas contra el coronavirus que llegarán a España. El Confidencial 2020:19 de agosto. [Ref.ID 103705]

15.

Kramer AE. Russia approves coronavirus vaccine before completing tests. N Y Times (Print) 2020:11 de agosto. [Ref.ID 103704]

16.

Samper E. Laboratorios y Estados invierten miles de millones y se lanzan a la producción masiva de vacunas experimentales sin certezas sobre su eficacia. eldiario.es 2020:29 de julio. [Ref.ID 103703]

17.

Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

18.

Parsons L. US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine. PMLiVE 2020:3 de agosto. [Ref.ID 103701]

19.

Parsons L. Moderna looks to price COVID-19 vaccine at $50-$60 per course. PMLiVE 2020:29 de julio. [Ref.ID 103700]

20.

Parsons L. US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine. PMLiVE 2020:23 de julio. [Ref.ID 103697]